F S&P 500
5,118.25 +36.00 (+0.71%) F Dow Jones
38,335.00 +47.00 (+0.12%) F Nasdaq
17,744.50 +177.00 (+1.01%) E-mini Russell 2000 Index Futur
1,991.00 -2.20 (-0.11%) Petróleo
83.87 +0.30 (+0.36%) Oro
2,357.80 +15.30 (+0.65%)
uniQure N.V. (QURE)
Fuera de horario:
uniQure N.V.
Paasheuvelweg 25
Amsterdam 1105 BP
Netherlands
31 20 240 6000
https://www.uniqure.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 480
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Matthew Craig Kapusta | CEO & Executive Director | 1.02M | N/D | 1972 |
| Mr. Christian Klemt | CFO, Principal Financial Officer & GM of Amsterdam Site | 575.46k | N/D | 1973 |
| Mr. Pierre Caloz | Chief Operating Officer | 882.59k | N/D | 1972 |
| Dr. Tamara Tugal Ph.D., MBA | Business Development Director | N/D | N/D | N/D |
| Ms. Carla Poulson | Interim Chief People and Culture Officer | N/D | N/D | N/D |
| Ms. Maria E. Cantor | Chief Corporate Affairs Officer | 491.12k | N/D | 1968 |
| Dr. Amin Abujoub Ph.D. | Chief Quality Officer | N/D | N/D | N/D |
| Dr. Walid Abi-Saab M.D. | Chief Medical Officer | N/D | N/D | 1965 |
| Eileen Sawyer | Vice President of Global Medical Affairs | N/D | N/D | N/D |
Descripción
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Gestión corporativa
La calificación ISS Governance QuickScore de uniQure N.V. a partir del 1 de abril de 2024 es 2. Las puntuaciones principales son Auditoría: 5; Junta: 3; Derechos del accionista: 1; Compensación: 5.
